SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01555697
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Cognitive training is moderately effective at reducing symptoms and improving life function
in schizophrenia patients. The present application develops a strategy for increasing the
effectiveness of cognitive training through the use of pro-cognitive medications. Specific
biomarkers will be studied that identify patients most sensitive to these pro-cognitive
medications, to test the feasibility of using these biomarkers in a large clinical trial of
medication-enhanced cognitive training in schizophrenia.
Name: Memantine
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Type: Drug
Group Labels: 1 Memantine
Name: Placebo
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Type: Drug
Primary Outcomes
Description: Prepulse inhibition of the startle reflex
Measure: Prepulse inhibition
Time: 3 years
Secondary Outcomes
Description: MATRICS Consensus Cognitive Battery Performance
Measure: MATRICS
Time: 3 years
Purpose: Health Services Research
Allocation: Randomized
Crossover Assignment
There is one SNP
SNPs
1 V158M
PPI-enhancing effects of MEM in healthy subjects are
associated with: 1) increased WM; and 2) phenotypes linked to the high activity Val158Met
COMT polymorphism. --- Val158Met ---
HPO Nodes
HPO: